A B, M N, B P, M F, et al. Switching from intra-venous to subcutaneous infliximab is safe and feasible in patients with inflammatory bowel disease suffering from obesity: a post-hoc analysis of the REMSWITCH study. Clin Gastroenterol Hepatol 2023 Oct 4:S1542-3565(23)00766.
PMID: 37802269